ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Rejection"

  • 2022 American Transplant Congress

    Characterization of Kidney Allograft Pathology Using the Histomap Gene Expression Profile (GEP) and Formalin Fixed Paraffin Embedded (FFPE) Tissue

    N. Garg1, K. Degner2, H. Zhang3, W. Tian3, F. Aziz4, S. Parajuli2, W. Zhong2, N. Wilson2, S. Panzer1, A. Djamali2

    1University of Wisconsin Madison, Madison, WI, 2University of Wisconsin, Madison, WI, 3CareDx, Brisbane, CA, 4University of Wsiconsin, Madison, WI

    *Purpose: The new Banff Human Organ Transplant (B-HOT) gene panel assessed on nCounter system has been created through a collaboration between NanoString and the Banff…
  • 2022 American Transplant Congress

    Defining New Arterial and Arteriolar Lesions Accompanying Transplant Glomerulopathy: Potential Additions to the Histologic Assessment of ABMR

    A. Perkowska-Ptasinska1, D. Deborska-Materkowska2, M. Ciszek3, M. Myslak4, J. Chang5, J. Reeve6, P. Halloran7

    1Pathology, Medical University of Warsaw, Warsaw, Poland, 2Transplantation Medicine, Nephrology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland, 3Immunology, Transplantation Medicine and Internal Diseases, Medical University of Warsaw, Warsaw, Poland, 4Infectious Diseases, Hepatology and Liver Transplantation, Pomeranian Medical University, Szczecin, Poland, 5Alberta Transplant Applied Genomics Center, Edmonton, AB, Canada, 6Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, 7Pathology, Alberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, AB, Canada

    *Purpose: Transplant glomerulopathy (TG) results from chronic endothelial injury most commonly related to ABMR. Surprisingly, except for PTC, the relation between TG and other vascular…
  • 2022 American Transplant Congress

    Regulatory T and B Cell Responses Are Equally Compromised During Antibody-Mediated Rejection of Kidney Allografts

    K. Louis1, P. Fadakar2, C. Macedo2, M. Yamada2, M. Lucas2, X. Gu2, A. Zeevi2, P. Randhawa2, C. Lefaucheur3, D. Metes2

    1Inserm U976, Human Immunology and Immunopathology, Paris, France, 2Surgery, University of Pittsburgh, Pittsburgh, PA, 3Inserm U970, Paris Translational Research Center for Organ Transplantation, Paris, France

    *Purpose: Although considerable advances have been made in understanding the cellular effector mechanisms responsible for donor-specific antibody (DSA) generation leading to antibody-mediated rejection (ABMR), the…
  • 2022 American Transplant Congress

    Clinical Validation of Automated Urinary Chemokine Assays for Non-Invasive Detection of Kidney Transplant Rejection: A Large Prospective Cohort Study

    E. Van Loon1, C. Tinel1, J. Callemeyn1, M. Coemans1, A. Van Craenenbroeck1, T. Vaulet2, D. Anglicheau3, M. Naesens1

    1Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium, 2ESAT STADIUS Center for Dynamical Systems, KU Leuven, Leuven, Belgium, 3Department of Nephrology and Kidney Transplantation, Necker Hospital, Paris, France

    *Purpose: Non-invasive diagnostic markers for kidney transplant rejection can provide useful information but often do not reach the clinical implementation stage. The chemokines CXCL9 and…
  • 2022 American Transplant Congress

    Modern Medicine Needs Modern Technology Tools

    Z. S. Soltani,, S. Soltani

    Ochsner Foundation Hospital, New Orleans, LA

    *Purpose: Dd-cfDNA has been used as a non-invasive biomarker for allograft injury and has been shown to detect subclinical rejection with higher predictive power compare…
  • 2022 American Transplant Congress

    Can dd-cf DNA Eliminate Unnecessary Biopsies? The Answer is Yes!

    K. Andreoni, Y. Chalicheemala, M. Debroy, M. Maklad, K. Zhao, M. Aeder, A. Jittirat, D. Ecabert, A. Bixby, C. Burrelli, K. Chavin

    University Hospitals Cleveland Medical Center, Cleveland, OH

    *Purpose: Historically our center has been one that routinely performs biopsies. We perform them pre-perfusion, for slowly recovering allografts between day 10-14, and routinely at…
  • 2022 American Transplant Congress

    Optimizing Kidney Transplant Immunosuppression Using a Phenotypic Personalized Dosing Model

    J. F. Bruner1, N. Padmanabhan2, C. Ho2, A. Zarrinpar1

    1Surgery, University of Florida, Gainesville, FL, 2Bioengineering, University of California, Los Angeles, Los Angeles, CA

    *Purpose: Immunosuppression is essential for preventing rejection and promoting long-term graft survival following solid organ transplantation; it also places patients at risk for infection and…
  • 2022 American Transplant Congress

    Baseline Levels and Early Post-Transplant Kinetics of Donor-Derived Cell-Free DNA Following Liver Transplantation

    S. Florman1, D. Axelrod2, J. Miles3, E. Vaskova3, D. Kilam3, K. Dhanireddy4, V. Subramanian4

    1Mount Sinai Medical Center, New York, NY, 2University of Iowa, Iowa City, IA, 3CareDx, South San Francisco, CA, 4Tampa General Hospital, Tampa, FL

    *Purpose: Non-invasive biomarkers in liver transplant (LT) are needed to improve detection of allograft injury in routine surveillance and during immunosuppression modulation, prior to the…
  • 2022 American Transplant Congress

    Early Detection of Acute Rejection by Urine QSant is Not Confounded by Post-Transplant Time

    C. Baan1, S. Ghosh2, J. Verhoeven1, D. Hesselink1, K. Boer1, M. Sarwal2

    1Erasmus MC, Rotterdam, Netherlands, 2NephroSant, Brisbane, CA

    *Purpose: We explore the viability of urinary biomarker-based monitoring for rejection in early days following renal transplantation.*Methods: Patients are from the Erasmus MC and received…
  • 2022 American Transplant Congress

    BiomarkeR Initiative to Advance Transplantation OutcomEs in Children (BRITE-c) Analysis

    M. E. Seifert1, L. Sheward2, A. Kho2, N. Rodig2, V. Dharnidharka3, M. Diehl2, R. B. Mannon4, O. Bestard5, T. Blydt-Hansen6, D. M. Briscoe2

    1University of Alabama, Birmingham, AL, 2Boston Children's Hospital, Boston, MA, 3St Louis Children's Hospital, St Louis, MO, 4University of Nebraska, Omaha, NE, 5Bellvitge University Hospital, Barcelona, Spain, 6BC Childrens, Vancouver, BC, Canada

    *Purpose: Recent studies indicate that 25-36% of clinically stable pediatric renal transplant recipients will have subclinical rejection detected on surveillance biopsy. These findings highlight a…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 172
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences